Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
BCAL Diagnostics Limited ( (AU:BDX) ) has shared an announcement.
BCAL Diagnostics Limited is on the verge of commercially launching its innovative breast cancer screening test, BREASTEST®, at the Sydney Breast Clinic in the first quarter of 2025. The company’s recent achievements, including NATA laboratory accreditation, publication in a peer-reviewed journal, and R&D tax incentives, position it well for market expansion. Additionally, BCAL’s strategic efforts include securing partnerships and licensing opportunities to broaden access to BREASTEST® and accelerating its launch in the US market.
More about BCAL Diagnostics Limited
BCAL Diagnostics Limited operates in the healthcare industry, specializing in breast cancer screening and diagnostics. The company’s primary product is the BREASTEST®, a novel blood test for detecting early-stage breast cancer, with a market focus on expanding its reach within Australian and US markets.
YTD Price Performance: -7.00%
Average Trading Volume: 434,139
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$34.04M
Learn more about BDX stock on TipRanks’ Stock Analysis page.
